Product information and disease descriptionProduct description
Phase of product development
24 evidence topics · 21 sources
Regulatory status: Under review; NDA accepted July 2026, PDUFA target action date April 2027
Launch: Anticipated in 2027
Investigational status and approval uncertainty
European Medicines Agency marketing authorization application
NDA submission timing, May 2026, superseded in July 2026
NDA submission timing, April 2026, superseded in July 2026
NDA submission timing, January 2026, superseded in July 2026
NDA submission timing, December 2025, superseded in July 2026
NDA submission timing, July 2025, superseded in July 2026
RAPIDe-3 topline timing, January 2025, superseded in July 2025
Development history: duration of the development program
Development history: phase 1 studies and the RAPIDe-1 phase 2 trial
Development history: RAPIDe-3 initiation, enrollment, and topline results
Development history: RAPIDe-2 open-label extension
Development history: CHAPTER-1, CHAPTER-3, and CHAPTER-4 prophylaxis trials of deucrictibant
Development history: CREAATE in acquired angioedema due to C1 inhibitor deficiency
FDA clinical hold, August 2022, and its lifts in June 2023 and January 2024
FDA orphan drug designation
| Field | Quoted record |
|---|---|
| Generic name | “deucrictibant” |
| Date designated | “03/18/2022” |
| Orphan designation | “Treatment of bradykinin-mediated angioedema (hereditary or acquired)” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Pharvaris GmbH” |
Orphan designations in the European Union and Switzerland
| Field | Quoted record |
|---|---|
| Active substance | “deucrictibant monohydrate” |
| Intended use | “Treatment of bradykinin-mediated angioedema” |
| EU designation number | “EU/3/25/3040” |
| Date of designation | “25/03/2025” |
| Sponsor | “Pharvaris Netherlands B.V.” |
EU paediatric investigation plan, agreed October 2023 and modified January 2025
FDA expedited program designations
No evidence found.